Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

Objective To analyse the available evidence on cardiovascular safety of non-steroidal anti-inflammatory drugs. Design Network meta-analysis. Data sources Bibliographic databases, conference proceedings, study registers, the Food and Drug Administration website, reference lists of relevant articles, and reports citing relevant articles through the Science Citation Index (last update July 2009). Manufacturers of celecoxib and lumiracoxib provided additional data. Study selection All large scale randomised controlled trials comparing any non-steroidal anti-inflammatory drug with other non-steroidal anti-inflammatory drugs or placebo. Two investigators independently assessed eligibility. Data extraction The primary outcome was myocardial infarction. Secondary outcomes included stroke, death from cardiovascular disease, and death from any cause. Two investigators independently extracted data. Data synthesis 31 trials in 116 429 patients with more than 115 000 patient years of follow-up were included. Patients were allocated to naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib, lumiracoxib, or placebo. Compared with placebo, rofecoxib was associated with the highest risk of myocardial infarction (rate ratio 2.12, 95% credibility interval 1.26 to 3.56), followed by lumiracoxib (2.00, 0.71 to 6.21). Ibuprofen was associated with the highest risk of stroke (3.36, 1.00 to 11.6), followed by diclofenac (2.86, 1.09 to 8.36). Etoricoxib (4.07, 1.23 to 15.7) and diclofenac (3.98, 1.48 to 12.7) were associated with the highest risk of cardiovascular death. Conclusions Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. Naproxen seemed least harmful. Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug.

[1]  L. Smeeth,et al.  A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example , 2009, PLoS medicine.

[2]  V. Welch,et al.  Oral or transdermal opioids for osteoarthritis of the knee or hip. , 2009, The Cochrane database of systematic reviews.

[3]  B. Kuehn.  FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. , 2009, Journal of the American Medical Association (JAMA).

[4]  D. DeMets,et al.  Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial , 2008, The Lancet.

[5]  S. Solomon,et al.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2008, Circulation.

[6]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[7]  S. Ebrahim.  Numbers Needed to Treat Derived from Meta‒Analyses: Pitfalls and Cautions , 2008 .

[8]  J. Avorn.  Keeping science on top in drug evaluation. , 2007, The New England journal of medicine.

[9]  J. Cairns.  The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks. , 2007, The Canadian journal of cardiology.

[10]  R. Chou,et al.  Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. , 2007, Journal of clinical epidemiology.

[11]  Kerrie Mengersen,et al.  Bayesian methods in meta-analysis , 2018 .

[12]  C. Bombardier,et al.  Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2006, The Lancet.

[13]  E. Ding,et al.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. , 2006, JAMA.

[14]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[15]  F. Jamali,et al.  EXTENT OF RENAL EFFECT OF CYCLO‐OXYGENASE‐2‐SELECTIVE INHIBITORS IS PHARMACOKINETIC DEPENDENT , 2006, Clinical and experimental pharmacology & physiology.

[16]  Nicola J Cooper,et al.  Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. , 2006, Archives of internal medicine.

[17]  J. Avorn,et al.  Patterns of cardiovascular risk in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[18]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[19]  J. Borer.  Cyclooxygenase Inhibition: What Should We Do to Resolve the Confusion? An American Perspective , 2006, Journal of cardiovascular pharmacology.

[20]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[21]  Jeffrey M Drazen,et al.  Expression of concern reaffirmed. , 2006, The New England journal of medicine.

[22]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[23]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[24]  N. Braunstein,et al.  Report of specific cardiovascular outcomes of the ADVANTAGE trial. , 2005, Annals of internal medicine.

[25]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[26]  B. Pitt,et al.  The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus , 2005 .

[27]  R. Hirsch,et al.  Frequent monthly use of selected non‐prescription and prescription non‐narcotic analgesics among U.S. adults , 2005, Pharmacoepidemiology and drug safety.

[28]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[29]  Thomas Brabant,et al.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[30]  R. Stafford,et al.  National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.

[31]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[32]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[33]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[34]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[35]  J. Fries,et al.  The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[36]  Alexander J Sutton,et al.  What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.

[37]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  M. Doherty,et al.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials , 2004, Annals of the rheumatic diseases.

[39]  F. Ruschitzka,et al.  Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension , 2003, Circulation.

[40]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[41]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[42]  J. Sterne,et al.  How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. , 2003, Health technology assessment.

[43]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[44]  F. Wolfe,et al.  Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. , 2002, The Journal of rheumatology.

[45]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[46]  John Simes,et al.  Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours , 2001, The Lancet.

[47]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[48]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[49]  A Whitehead,et al.  Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.

[50]  D J Spiegelhalter,et al.  Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.

[51]  D G Altman,et al.  Statistics notes: Absence of evidence is not evidence of absence , 1995 .

[52]  M. Clarke,et al.  Identifying relevant studies for systematic reviews , 1995, BMJ.

[53]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[54]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.